In vivo dendritic cell reprogramming for cancer immunotherapy

Antigen presentation and immune cell exclusion limit the broad success of immunotherapy. Prof. Filipe Pereira’s groundbreaking in vivo approach addresses these issues by reprogramming tumor cells into antigen-presenting dendritic cells. The reprogrammed cells are capable of remodeling their microenvironment, activating cytotoxic T cells, and establishing lasting immunity.

What you will learn in this webinar?​

• Tumor cell reprogramming as an approach for off-the-shelf cancer immunotherapies.
• How immunosuppressive tumor microenvironment negatively impacts therapy outcomes.
• In vivo tumor remodeling to trigger potent anti-tumor immunity.
• Preclinical success of reprogramming-based immunotherapy sets stage for clinical trials.

SPEAKER

Prof. Filipe Pereira
Professor of Molecular Medicine at Lund University
Co-founder & Head of Innovation at Asgard Therapeutics